^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD25-targeted antibody-drug conjugate

    Related drugs:
    2ms
    A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors (clinicaltrials.gov)
    P1, N=11, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting | N=185 --> 11 | Trial completion date: Jun 2030 --> Feb 2026 | Trial primary completion date: Jun 2029 --> Feb 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    2ms
    A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers (clinicaltrials.gov)
    P1, N=6, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting | N=220 --> 6 | Trial completion date: Apr 2029 --> Feb 2026 | Trial primary completion date: Jan 2029 --> Feb 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    sasanlimab (PF-06801591)
    6ms
    A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies (clinicaltrials.gov)
    P1, N=399, Recruiting, Pfizer | Not yet recruiting --> Recruiting | Trial completion date: Feb 2029 --> Jul 2029 | Trial primary completion date: Feb 2028 --> Jul 2028
    Enrollment open • Trial completion date • Trial primary completion date
    |
    sasanlimab (PF-06801591)
    6ms
    A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors (clinicaltrials.gov)
    P1, N=185, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open
    7ms
    A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers. (clinicaltrials.gov)
    P1, N=220, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    sasanlimab (PF-06801591)
    7ms
    A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies (clinicaltrials.gov)
    P1, N=399, Not yet recruiting, Pfizer
    New P1 trial
    |
    sasanlimab (PF-06801591)
    7ms
    PF-08046032: A novel, investigational CD25-directed antibody-drug conjugate optimized for selective depletion of regulatory T cells in advanced malignant tumors. (PubMed, Mol Cancer Ther)
    Lastly, PF-08046032 was well-tolerated in non-human primates and mitigated the persistent depletion of peripheral blood Treg that was observed with a high affinity anti-CD25 ADC comparator, demonstrating the safety benefit of a detuned affinity ADC format. PF-08046032 represents an innovative therapeutic approach for depletion of intratumoral Tregs that may offer an improved safety profile and efficacy over traditional Treg depleting agents.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IL2RA (Interleukin 2 receptor, alpha) • IL2 (Interleukin 2)
    |
    IL2RA expression
    9ms
    A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers. (clinicaltrials.gov)
    P1, N=220, Not yet recruiting, Pfizer
    New P1 trial
    |
    sasanlimab (PF-06801591)
    9ms
    This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1. (clinicaltrials.gov)
    P3, N=714, Not yet recruiting, Pfizer | Initiation date: Jan 2025 --> May 2025
    Trial initiation date
    |
    Keytruda (pembrolizumab) • sigvotatug vedotin (PF-08046047)
    over1year
    Targeting CD25+ lymphoma cells with the antibody-drug conjugate camidanlumab tesirine as a single agent or in combination with targeted agents. (PubMed, Br J Haematol)
    When camidanlumab tesirine-containing combinations were evaluated in four T-cell lymphoma models, the most active partners were everolimus, copanlisib, venetoclax, vorinostat, and pralatrexate, followed by bortezomib, romidepsin, bendamustine, and 5-azacytidine. The strong camidanlumab tesirine single-agent anti-lymphoma activity and the in vitro synergisms with targeted agents identify potential combination partners for future clinical studies.
    Journal • Combination therapy
    |
    IL2RA (Interleukin 2 receptor, alpha)
    |
    Venclexta (venetoclax) • everolimus • bortezomib • azacitidine • Aliqopa (copanlisib) • Zolinza (vorinostat) • bendamustine • Istodax (romidepsin) • camidanlumab tesirine (ADCT-301) • Folotyn (pralatrexate)
    over1year
    Study of ADCT-301 in Patients With Selected Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=78, Terminated, ADC Therapeutics S.A. | Phase classification: P1b --> P1
    Phase classification • Metastases
    |
    MSI (Microsatellite instability)
    |
    Keytruda (pembrolizumab) • camidanlumab tesirine (ADCT-301)